Monday, June 11, 2012

ECDC Response Plan To Multi-Drug Resistant Gonorrhea

 

 

# 6379

 

 

Last week in WHO: Urgent Action Needed On Resistant Gonorrhea, I updated a story that Maryn McKenna and I have both written about on several occasions over the past couple of years; the worrisome rise in antibiotic-resistant gonorrhea around the globe.

 

Early last month Maryn wrote Drug-Resistant Gonorrhea: How We Lost Track and last year she penned The Clap Came Back: Multidrug-Resistant Gonorrhea, both of which are highly recommended reading.

 

You’ll find a couple of my earlier offerings here, and here.

 

Today the ECDC has released a series of reports, including a 23-page technical document with their response plan to control and manage the threat of multidrug-resistant gonorrhea in Europe.

 

image

 

 

Released today as well is a 41-page document called Gonococcal antimicrobial susceptibility surveillance in Europe – 2010, that finds a worrisome trend:

 

image

Euro-GASP 2010 identified a significant increase in the proportion of tested isolates that show decreased susceptibility to cefixime, from 4% in 2009 to 9% in 2010, using a cut-off of >0.125 mg/L. Rates of ciprofloxacin and azithromycin resistance remain high (53% and 7%, respectively).

 


Along with the two report, the ECDC has released their surveillance report Sexually transmitted infections in Europe 1990-2010, tracking the spread and prevalence of five STI’s (syphilis, congenital syphilis, gonorrhoea, chlamydia and lymphogranuloma  venereum (LGV)) across the EU over the past 2 decades.

 

Details and links follow:

 

 

 

Concerns about future treatment of gonorrhoea in Europe: ECDC issues response plan

11 Jun 2012

ECDC

With more than 32 000 cases, gonorrhoea was the second most commonly reported sexually transmitted infection (STI) in Europe in 2010. As data from the ECDC report Gonococcal antimicrobial susceptibility surveillance in Europe 2010 illustrates, gonococci have become more resistant to common agents for treatment and show reduced susceptibility to newer antibiotics. “This indicates the risk that gonorrhoea may become an untreatable disease in the near future”, stresses ECDC Director Marc Sprenger.


In response to these signals, ECDC today also publishes its Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe.

 

Results from the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)  show that the percentage of isolates with decreased susceptibility to the recommended drug for treatment of gonorrhoea (cefixime) rose from 4% in 2009 to 9% in 2010. Decreased susceptibility was detected in 17 countries in 2010, seven more than in the previous year.

 

“Decreasing susceptibility to recommended antimicrobials and increasing numbers of treatment failures across Europe ask for careful monitoring of the European gonococcal population as the as the loss of the current recommended treatments could result in untreatable gonorrhoea”, says ECDC Director Marc Sprenger.

Read more

 

 

The problem of antibiotic resistance isn’t restricted to Neisseria gonorrhoeae, of course. The list of resistant bacteria is long and continues to expand, including such high profile pathogens as MRSA, NDM-1, KPC, EHEC.

 

While the end of the antibiotic era is not yet at hand, the fear is - without new drugs and the proper stewardship of the ones we already have - we may be drawing closer to that day.

 

A few of my blogs on the subject include:

 

UK: `New MRSA’ Strain Spreading
CMAJ: Local Acquisition Of NDM-1 In Ontario
India Looks For (And Finds) NDM-1
Carbapenemases Rising
WHO: The Threat Of Antimicrobial Resistance
NDM-1: A New Acronym To Memorize

 

And for a far more complete (and eye-opening) discussion of antimicrobial resistance issues, I can think of no better primer than Maryn McKenna’s book SUPERBUG: The Fatal Menace of MRSA.

No comments: